PRX-14040 is a selective dopamine reuptake inhibitor that was developed by Prexa Pharmaceuticals.[1][2][3] It has 28-fold selectivity for the dopamine transporter over the norepinephrine transporter.[2] Similarly to various other dopamine reuptake inhibitors, the drug has been found to reverse motivational deficits induced by the dopamine depleting agent tetrabenazine in animals.[1][2]

See also

References

  1. ^ a b Salamone JD, Correa M, Ferrigno S, Yang JH, Rotolo RA, Presby RE (October 2018). "The Psychopharmacology of Effort-Related Decision Making: Dopamine, Adenosine, and Insights into the Neurochemistry of Motivation". Pharmacol Rev. 70 (4): 747–762. doi:10.1124/pr.117.015107. PMC 6169368. PMID 30209181.
  2. ^ a b c Desibhatla, Mukund (16 June 2021). "The Development and Evaluation of Novel DA Transport Inhibitors and their Effects on Effort-Related Motivation: A Review". Honors Scholar Theses. Retrieved 10 August 2024.
  3. ^ Yohn SE, Gogoj A, Haque A, Lopez-Cruz L, Haley A, Huxley P, Baskin P, Correa M, Salamone JD (September 2016). "Evaluation of the effort-related motivational effects of the novel dopamine uptake inhibitor PRX-14040". Pharmacol Biochem Behav. 148: 84–91. doi:10.1016/j.pbb.2016.06.004. PMID 27296079.


Allikas: https://en.wikipedia.org/wiki/PRX-14040
No tags for this post.